Human papilloma virus E1-specific T cell immune response is associated with the prognosis of cervical cancer patients with squamous cell carcinoma

Table 2 The relationship between response frequency of HPV E1-specific T cell response in peripheral blood and clinical features in patients with cervical squamous cell carcinoma

Factor		N	Frequency (%)	χ ²	P-value
Age (year)	≤54	32	53.13	0.915	0.339
Age (year)	> 54	34	64.71	0.915	0.339
Family history of cancer	No	59	57.63	0.678	0.767
Family history of cancer	Yes	7	71.43	0.678	0.767
History of miscarriage	No	30	56.67	0.134	0.715
History of miscarriage	Yes	36	61.11	0.134	0.715
Tumor size (cm)	≤5	43	58.14	0.046	0.830
Tumor size (cm)	> 5	23	60.87	0.046	0.830
Tumor type	Cauliflower	25	52.00	1.868	0.60
	Nodular	29	58.62
	Hollow	7	71.43
	Others	5	80.00
Histologic grade	Well	2	0	4.465	0.215
	Moderate	45	64.44
	Poor	13	53.85
	Papillary	6	50.00
FIGO stage	IIB	34	59.38	0.002	0.964
FIGO stage	IIIA-IIIB	32	58.82	0.002	0.964
SCC-Ag	Normal	12	75.00	1.536	0.215
SCC-Ag	Anormal	54	55.56	1.536	0.215
CEA	Normal	42	64.29	1.289	0.256
CEA	Anormal	24	50.00	1.289	0.256
TSGF	Normal	46	54.35	1.413	0.235
TSGF	Anormal	20	70.00	1.413	0.235
Pelvic lymph nodes	No	37	64.86	1.161	0.281
Pelvic lymph nodes	Yes	29	51.72	1.161	0.281

N number of patients, FIGO International Federation of Gynecology and Obstetrics, SCC-Ag Squamous cell carcinoma antigen, CEA carcinoembryonic antigen, TSGF Tumor specific growth factor

ISSN: 1750-9378